Roche Holding AG - Free Cash Flow To Equity
Roche Holding AG's Fiscal Year is From January To December - All Figures are in CHF, Billions.
The item "Free-Cash-Flow-To-Equity" stands at 8.92 Billion Swiss Francs for the trailing twelve months (TTM) period ending 06/30/2025, the lowest value since 06/30/2017.'
Regarding the One-Year-Change of the series, the current value constitutes an decrease of -11.56 Billion Swiss Francs compared to the value the year prior.
The 1 year change is -11.56 Billion Swiss Francs.
The 3 year change is -29.77 Billion Swiss Francs.
The 5 year change is -10.37 Billion Swiss Francs.
The 10 year change is 12.37 Billion Swiss Francs.
The Serie's change in Swiss Francs from it's minimum value, on 06/30/2013, to it's latest available value, on 06/30/2025, is +21.62 Billion.
The Serie's change in Swiss Francs from it's maximum value, on 12/31/2021, to it's latest available value, on 06/30/2025, is -32.09 Billion.
Free Cash Flow To Equity for Related Companies:
| Logo | Name | Market Cap (USD) |
|---|---|---|
 | Eli Lilly and Company - Free Cash Flow To Equity | 905,699,262,464.00 |
 | Johnson & Johnson - Free Cash Flow To Equity | 486,508,953,600.00 |
 | AbbVie Inc - Free Cash Flow To Equity | 399,570,305,024.00 |
 | AstraZeneca PLC - Free Cash Flow To Equity | 280,205,508,085.11 |
 | Novartis AG - Free Cash Flow To Equity | 255,096,620,580.91 |